Phase I dose escalation of single-agent vinblastine in dogs.

@article{Bailey2008PhaseID,
  title={Phase I dose escalation of single-agent vinblastine in dogs.},
  author={Dennis B. Bailey and Kenneth M. Rassnick and O. A. Kristal and John D Chretin and Cheryl E. Balkman},
  journal={Journal of veterinary internal medicine},
  year={2008},
  volume={22 6},
  pages={
          1397-402
        }
}
BACKGROUND Vinblastine (VBL) is commonly used in dogs at a dosage of 2.0 mg/m2. The minimal toxicity observed at this dosage indicates that higher dosages might be well tolerated. HYPOTHESIS The maximum tolerated dosage (MTD) for a single VBL treatment is higher than the previously published dosage of 2.0 mg/m2. ANIMALS Twenty-three dogs with lymphoma or cutaneous mast cell tumors. METHODS Dogs received 1 single-agent VBL treatment IV. The starting dosage was 3.0 mg/m2, and dosages were… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Dose and outcome: the hurdle of neutropenia (Review).

Oncology reports • 2006
View 4 Excerpts
Highly Influenced

Antimicrotubule agents

EK Rowinsky
Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, Practice and Principles, • 2006
View 1 Excerpt

Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas

KM Rassnick, AS Moore, NC Northrup
Am J Vet Res • 2006
View 1 Excerpt